[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100479779":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":36,"responsibleParty":51,"collaborators":25,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":25,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":25,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Institut d'Investigacions Biomèdiques August Pi i Sunyer","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dasatinib","EXPERIMENTAL","Dasatinib monotherapy (70 mg\u002Fday) will be given for 4 weeks. Antiretroviral therapy (ART) based on unboosted integrase inhibitors will be initiated at week 4 (S4) and dasatinib will be continued with ART until week 12.",[13],"Drug: Dasatinib",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo monotherapy will be given for 4 weeks. Antiretroviral therapy (ART) based on unboosted integrase inhibitors will be initiated at week 4 (S4) and placebo will be continued with ART until week 12.",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Dasatinib monotherapy 70 mg\u002Fday, during 16 weeks.",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Placebo during 16 weeks.",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":34,"email":35},"Eva Bonfill","CONTACT","+34 932275400","4198","bonfill@recerca.clinic.cat",[37],{"facility":31,"status":38,"city":39,"state":25,"zip":25,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Barcelona","Spain","ES",{"type":43,"coordinates":44},"Point",[45,46],2.15899,41.38879,{"lat":46,"lon":45},[49],{"name":31,"role":32,"phone":50,"phoneExt":34,"email":35},"932 257 400",{"type":52,"investigatorFullName":31,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Clinical Research Manager","100479779","phase-2-safety-tolerance-and-antiretroviral-activity-of-dasatinib-a-pilot-clinical-trial-in-patients-with-recent-hiv-1-infection-100479779",false,"NCT05527418","Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection","DASAHIVCURE","Inclusion Criteria:\n\n* 18 to 65 years.\n* Documented asymptomatic HIV-1 infection of 3-12 months duration (all patients must have a positive Western blot, including the p31 band whose appearance indicates infection of more than 90 days duration).\n* Not having received ART\n* CD4 T-lymphocyte count\\> 350 \u002F μl\n* Patient giving written informed consent\n\nExclusion Criteria:\n\n* Active HBV (HBsAg+ or DNA+) and\u002For HCV (RNA+) infection in screening.\n* ALT\\> 2 UNL, glomerular filtration rate \\\u003C70 mL \u002F 1.73 m2, leukocytes \\\u003C4000 \u002F mm3, total lymphocyte count \\\u003C1000 \u002F mm3, platelets \\\u003C100,000 \u002F mm3 or Hg \\\u003C12g \u002F dL.\n* Pregnancy or active breastfeeding\n* Ongoing or previous pleural effusion\n* Chronic obstructive pulmonary disease, bronchial asthma or recent chest trauma.\n* History of gastrointestinal or other bleeding.\n* Any concomitant treatment with potentially dangerous drug interaction with dasatinib.\n* Any clinical condition, at the opinion of the investigator, contraindicating participation (for example,\n* Active neoplastic disease, active concomitant infection, etc.)","ALL","18 Years","65 Years",{"count":65,"type":66},24,"ESTIMATED","INTERVENTIONAL",[69],"PHASE2","Study to evaluate the safety, tolerability and antiretroviral activity of a new therapeutic strategy, based on the administration of dasatinib, an ITK, in patients with recent (3-12 months) asymptomatic HIV-1 infection.",[72],"Recent HIV-1 Infection","2025-04-30",{"date":75,"type":76},"2025-05-01","ACTUAL",{"date":78,"type":76},"2024-01-26",{"date":80,"type":66},"2026-06",{"name":31,"class":6},1]